ArticleCPT: pharmacometrics & systems pharmacology2012
Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.
Article in CPT: pharmacometrics & systems pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women.Clinical pharmacokinetics · 2023Trial
- A physiology-based mathematical model of the renin-angiotensin system, bone remodeling, and calcium homeostasis: Effects of estrogen and renin-angiotensin system inhibitors.PLoS computational biology · 2026Article
- Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis: Advances in Research.Journal of clinical medicine research · 2025Review
- Assessing the performance of QSP models: biology as the driver for validation.Journal of pharmacokinetics and pharmacodynamics · 2024Review
- A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis.British journal of clinical pharmacology · 2022Article
- Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.Clinical and translational science · 2021Article
- Computational Models for Diagnosing and Treating Endometriosis.Frontiers in reproductive health · 2021Review
- Pharmacometrics and systems pharmacology for metabolic bone diseases.British journal of clinical pharmacology · 2019Review
- Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT: pharmacometrics & systems pharmacology · 2016Article
- Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis.CPT: pharmacometrics & systems pharmacology · 2015Article
- Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).ACS medicinal chemistry letters · 2015Article
- FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?CPT: pharmacometrics & systems pharmacology · 2015Article
- A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes.CPT: pharmacometrics & systems pharmacology · 2015Article
- Implementation of quantitative and systems pharmacology in large pharma.CPT: pharmacometrics & systems pharmacology · 2014Review
- CPT: Pharmacometrics & Systems Pharmacology Publishes Its 100th Article.CPT: pharmacometrics & systems pharmacology · 2014Article
- Article
- Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.CPT: pharmacometrics & systems pharmacology · 2012Article
- Relugolix Combination Tablets in Healthy Japanese Premenopausal Women: Pharmacokinetics, Pharmacodynamics, and Safety Profile.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a gynecological condition resulting from proliferation of endometrial-like tissue outside the endometrial cavity. Estrogen suppression therapies, mediated through gonadotropin-releasing hormone (GnRH) modulation, decrease endometriotic implants and diminish associated pain albeit at the expense of bone mineral density (BMD) loss. Our goal was to provide model-based guidance for GnRH-modulating clinical programs intended for endometriosis management. This included developing an estrogen suppression target expected to provide symptomatic relief with minimal BMD loss and to evaluate end points and study durations supportive of efficient development decisions. An existing multiscale model of calcium and bone was adapted to include systematic estrogen pharmacologic effects to describe estrogen concentration-related effects on BMD. A logistic regression fit to patient-level data from three clinical GnRH agonist (nafarelin) studies described the relationship of estrogen with endometrial-related pain. Targeting estradiol between 20 and 40 pg/ml was predicted to provide efficacious endometrial pain response while minimizing BMD effects.CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e11; doi:10.1038/psp.2012.10; advance online publication 17 October 2012.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.